Navigation Links
New AHRQ Resources Help Primary Care Clinicians Treat Alcohol Use Disorder
Date:2/16/2016

ROCKVILLE, Md., Feb. 16, 2016 /PRNewswire-USNewswire/ -- The Agency for Healthcare Research and Quality (AHRQ) today published two new resources to help primary care clinicians and their patients make evidence-based decisions about which medications to use for treating alcohol use disorder (AUD), the medical diagnosis for problem drinking that causes mild to severe distress or harm.

The new resources – a pair of research summaries designed to facilitate treatment discussions between clinicians and patients – will make it easier for primary care clinicians to work with their patients to make treatment decisions about medications used to treat AUD. Primary care providers are typically trained to refer patients with AUD for specialized treatment, and fewer than 10 percent of people treated for AUD receive medications currently.

In the United States, more than 68 million people 18 years old or older suffer from AUD at some point in their lifetime, according to data released by the National Institute on Alcohol Abuse and Alcoholism in August 2015. The disorder can lead to severe health problems and immeasurable personal and family suffering. It is the third modifiable risk factor that leads to early death, after tobacco use and being overweight; people with AUD are at least three times as likely to die early as those without AUD.

"These new resources, based on the most current research, will help clinicians and patients make informed choices about treatment in accordance with their own wishes and values," said AHRQ Director Rick Kronick, Ph.D.

The research summaries are based on findings from a 2014 review of the evidence on medication-based treatment of AUD. One summary is directed at clinicians and other health care providers to help them understand the evidence currently available so they can apply it on the front lines of care. The other summary is written in a way that can help patients and their families understand what their options are for medication-based treatments.

AHRQ's systematic review found moderate evidence that acamprosate (trade name: Campral) and oral naltrexone (Reviva, Vivitrol) improve outcomes for patients with AUD. Head-to-head comparisons have not consistently established the superiority of one medication over another, and evidence related to injectable naltrexone is limited. The review also found that the evidence from randomized, placebo-controlled trials does not support the effectiveness of disulfiram (Antabuse) for clinical outcomes, such as a return to any drinking and number of drinks/per drinking days, or for reducing amount of alcohol consumed. 

Most studies included in the review evaluated the use of medications in conjunction with psychosocial treatments; the use of medications alone has not been studied enough to draw conclusions, according to the review.

Conducted by researchers funded through AHRQ's Evidence-based Practice Center program, the review included studies on medicines to treat alcohol dependence and alcohol use disorder published between January 1970 and October 2013. The report included 135 studies, and findings were reviewed by health care professionals, researchers, experts and the public. The full report is available at www.effectivehealthcare.ahrq.gov/alcohol-disorder.

AHRQ's Evidence-based Practice Centers develop systematic reviews to help the public, clinicians and others who make decisions about health care improve the quality of care provided in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions and new health care technologies and strategies. Select findings from these reviews are translated into guides so that clinicians and patients can easily apply the findings on the front lines of care. These new AUD research summaries and other guides and systematic reviews can be found at www.effectivehealthcare.ahrq.gov.

AHRQ's mission is to produce evidence to make health care safer, higher quality, more accessible, equitable and affordable, and to work with Department of Health and Human Services and other partners to make sure that the evidence is understood and used. For more information about AHRQ, visit www.ahrq.gov.

 

 


'/>"/>
SOURCE Agency for Healthcare Research & Quality
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Orexigen Therapeutics names Thomas Lynch as EVP, General Counsel & Secretary and Heather Ace as EVP, Global Human Resources
2. Hospice Pharmacy Solutions completes merger with Outcome Resources
3. Sign Against Stroke Task Force Help to Address Medical, Physical, Mental and Financial Needs of People with Atrial Fibrillation with New Health Empowerment Resources
4. West Appoints Annette Favorite Senior Vice President and Chief Human Resources Officer
5. Decision Resources Groups Monique Levy Appointed to Google Healthcare Advisory Board
6. Decision Resources Group Projects the US Market for Diabetes Care Devices To Be Valued at Over $22 Billion by 2023
7. NxStage Launches New Spanish-Language Resources for Hispanic Patients
8. Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance
9. Intarcia Appoints James P. Brady Vice President, Human Resources
10. Precyse Unlocks Revenue and Resources at HIMSS 2015
11. DigiPath Inc. Partners with Blue Line Protection Group to Share Resources and Develop Marketing Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... ... Center is now offering various types of dental implants to restore lost teeth. Dental implants ... such as crowns, bridges, or dentures. An implant is placed directly into the jawbone where ... tooth. , Several types of dental implants are available, including: , ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for ... the hiring of Richard Robinson as chief operating officer (COO). In this role, ... a proven track record of simplifying business processes and developing growth strategies to ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... leakage is revolutionizing the way women look and feel about themselves and their ... of female sexual dysfunction and urinary leakage head on with a ground breaking ...
(Date:6/26/2017)... , ... June 26, 2017 , ... ... staff, and consumers are seeing lots of red these days. According to recent ... charges that result from medical coding errors(1). Some studies point to Electronic Health ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with ... Angela Cotey, with or without a referral. Dr. Cotey is a trusted dentist who ... preferred tooth replacement option. , Patients with missing teeth in Fitchburg, WI, are encouraged ...
Breaking Medicine News(10 mins):